Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282312 | 0.87 | TAS1R3 (0.47) | CYP1A2HSP90AA1HSP90AB1BLMMLYCD | |
| SCHEMBL17151146 | 0.86 | CYP1A2 (0.47) | CYP1A2HSP90AA1HSP90AB1BLMCYP2C9 | |
| SCHEMBL4843412 | 0.84 | MLYCD (0.49) | MLYCDTAS1R3TAS1R1RAB9AKMT2A | |
| SCHEMBL5604944 | 0.82 | CYP1A2 (0.44) | CYP1A2HSP90AA1HSP90AB1BLMMLYCD | |
| SCHEMBL4568348 | 0.82 | MLYCD (0.48) | CYP1A2HSP90AA1HSP90AB1BLMMLYCD | |
| SCHEMBL970447 | 0.81 | RXFP1 (0.50) | CYP1A2HSP90AA1HSP90AB1BLMMLYCD | |
| SCHEMBL8988251 | 0.80 | MLYCD (0.45) | HSP90AA1HSP90AB1MLYCDMEN1RAB9A | |
| SCHEMBL15216403 | 0.80 | HPGD (0.59) | MLYCDTSHRMEN1RAB9AKMT2A | |
| SCHEMBL5776326 | 0.80 | HDAC1 (0.51) | MLYCDRAB9AKMT2ALMNAHTT | |
| SCHEMBL30480721 | 0.80 | MAPT (0.58) | MLYCDCYP3A4TSHRRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | ARDELYX, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3565811-A1 | INHIBITORS OF NHE-MEDIATED ANTIPORT | Ardelyx, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129557-A1 | INHIBITORS OF NHE-MEDIATED ANTIPORT | ARDELYX, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | CYP1A2 70/4885HSP90AA1 1832/4885HSP90AB1 1473/4885 |
| US-11147884-B2 | Inhibitors of NHE-mediated antiport | SLC10A1, SLC10A2, SLC9A2 | CYP1A2 2168/4885HSP90AA1 202/4885HSP90AB1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.